Gilead Sciences, Inc. (GILD) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/19/25
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan AfricaBusiness Wire • 11/18/25
GILD's Investigational Regimen for HIV Treatment Meets Primary GoalZacks Investment Research • 11/14/25
Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 TrialBusiness Wire • 11/13/25
Gilead Sciences, Inc. (GILD) Presents at UBS Global Healthcare Conference 2025 TranscriptSeeking Alpha • 11/10/25
Gilead's Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease ProgressionBusiness Wire • 11/07/25
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales DeclineZacks Investment Research • 11/04/25
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025Business Wire • 11/03/25
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales GrowZacks Investment Research • 10/31/25
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)Business Wire • 10/31/25
Covid Continues To Haunt Gilead. How One Drug Dinged Product Sales.Investors Business Daily • 10/30/25